GUD

Knight Therapeut

• Dow Jones·08/20 12:15

  Knight Therapeutics Gets Exchange Approval for Share Buyback Program

• Dow Jones·08/20 11:31

  *Knight Therapeutics to Buy Back Up to 3M Co. Common Shares Under NCIB >GUD.T

• Dow Jones·08/20 11:30

  *Knight Therapeutics Announces Normal Course Issuer Bid >GUD.T

• Dow Jones·08/07 11:37

  *Knight Therapeutics Increases 2025 Fincl Guidance

• Dow Jones·05/09 15:44

  Knight Therapeutics Inc. Price Target Is Maintained at C$6.50/Share by Canaccord Genuity

• Dow Jones·05/09 15:44

  Knight Therapeutics Inc. Is Maintained at Buy by Canaccord Genuity

• Dow Jones·05/08 11:40

  *Knight Therapeutics Backs 2025 Rev C$390M-C$405M >GUD.T

• Dow Jones·05/08 11:39

  *Knight Therapeutics Reconfirmed Its Fincl Guidance Targets for 2025 >GUD.T

• Dow Jones·05/08 11:30

  *Knight Therapeutics 1Q EPS C$0.02 >GUD.T

• Dow Jones·03/25 15:43

  Knight Therapeutics Inc. Price Target Raised to C$7.45/Share From C$6.25 by Stifel Nicolaus

• Dow Jones·03/25 15:43

  Knight Therapeutics Inc. Is Maintained at Buy by Stifel Nicolaus

• Dow Jones·03/20 11:33

  *Knight Therapeutics Sees 2025 Adjusted Ebitda About 13% of Revenue >GUD.T

• Dow Jones·03/20 11:32

  *Knight Therapeutics Sees 2025 Rev C$390M-C$405M >GUD.T

• Dow Jones·03/20 11:30

  *Knight Therapeutics 4Q EPS C$0.11 >GUD.T

• Dow Jones·03/12 15:46

  Knight Therapeutics Inc. Price Target Raised to C$8.00/Share From C$7.50 by Raymond James